The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Billeskov, Rolf ^a   Elvang, Tara T ^a   Andersen, Peter L ^a   Dietrich, Jes ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; H4 VACCINE; IC 31; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL VIRULENCE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; INFECTION PREVENTION; LYMPHOCYTE FUNCTION; MALE; MEMORY T LYMPHOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TUBERCULOSIS;

ANIMALS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; LUNG; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUBERCULOSIS; VACCINES, SUBUNIT; VIRULENCE;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84863109492     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039909     Document Type: Article

References (44)

1. WHO (2010) Global Tuberculosis Control- suirveillance, planning, financing. World Health Organisation, Geneva, Switzerland.
2. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, et al. (2002) Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis 185: 401-404.
3. Harries AD, Dye C, (2006) Tuberculosis. Ann Trop Med Parasitol 100: 415-431.
4. Fine PE, (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
5. Kipnis A, Irwin S, Izzo AA, Basaraba RJ, Orme IM, (2005) Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 Ligandhi population. Infect Immun 73: 7759-7764.
6. Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM, (2001) Boosting vaccine for tuberculosis. Infect Immun 69: 2714-2717.
7. Sterne JA, Rodrigues LC, Guedes IN, (1998) Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 2: 200-207.
8. Dourado I, Rios MH, Pereira SM, Cunha SS, Ichihara MY, et al. (2003) Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Int J Tuberc Lung Dis 7: 399-402.
9. Roth AE, Benn CS, Ravn H, Rodrigues A, Lisse IM, et al. (2010) Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ 340: c671.
10. Thom M, Howard C, Villarreal-Ramos B, Mead E, Vordermeier M, et al. (2008) Consequence of prior exposure to environmental mycobacteria on BCG vaccination and diagnosis of tuberculosis infection. Tuberculosis (Edinb) 88: 324-334.
11. Flaherty DK, Vesosky B, Beamer GL, Stromberg P, Turner J, (2006) Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination. J Leukoc Biol 80: 1262-1271.
12. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, et al. (2002) Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70: 672-678.
13. Hubbard RD, Flory CM, Collins FM, (1992) Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 87: 94-98.
14. Andersen P, (1994) Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62: 2536-2544.
15. Andersen P, Askgaard D, Ljungqvist L, Bentzon MW, Heron I, (1991) T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 59: 1558-1563.
16. Olsen AW, van Pinxteren LA, Okkels LM, Rasmussen PB, Andersen P, (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69: 2773-2778.
17. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P, (2004) Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72: 6148-6150.
18. Ottenhoff TH, Doherty TM, Dissel JT, Bang P, Lingnau K, et al. (2010) First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin 6 (12): 1007-15.
19. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, et al. (2001) Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. Jama 286: 1740-1747.
20. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T, (2005) Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 24: 529-536.
21. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, et al. (2005) Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174: 6332-6339.
22. Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, et al. (2009) Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 4: e5930.
23. Billeskov R, Grandal MV, Poulsen C, Christensen JP, Winther N, et al. (2010) Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. Eur J Immunol 40: 1342-1354.
24. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J, (2007) Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J Immunol 179: 3973-3981.
25. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
26. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
27. Rogerson BJ, Jung YJ, LaCourse R, Ryan L, Enright N, et al. (2006) Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology 118: 195-201.
28. Junqueira-Kipnis AP, Turner J, Gonzalez-Juarrero M, Turner OC, Orme IM, (2004) Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis. Infect Immun 72: 570-575.
29. Vordermeier HM, Chambers MA, Cockle PJ, Whelan AO, Simmons J, et al. (2002) Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun 70: 3026-3032.
30. Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, et al. (2002) Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 40: 704-706.
31. Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, et al. (2012) Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 30: 2811-2823.
32. Dey B, Jain R, Gupta UD, Katoch VM, Ramanathan VD, et al. (2011) A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS One 6: e23360.
33. Tchilian EZ, Desel C, Forbes EK, Bandermann S, Sander CR, et al. (2009) Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun 77: 622-631.
34. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181: 4955-4964.
35. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197: 563-571.
36. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, et al. (2010) Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 182: 1073-1079.
37. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, et al. (2010) Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 40: 2211-2220.
38. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, et al. (2011) Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 187: 2222-2232.
39. Bold TD, Banaei N, Wolf AJ, Ernst JD, (2011) Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLoS Pathog 7 (5): e1002063.
40. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, et al. (2006) Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 177: 6353-6360.
41. Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, et al. (2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
42. Bakir M, Millington KA, Soysal A, Deeks JJ, Efee S, et al. (2008) Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 149: 777-787.
43. Lienhardt C, Fielding K, Hane AA, Niang A, Ndao CT, et al. (2010) Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 5: e10508.
44. Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, et al. (2010) Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 28: 1084-1093.